Risk of health-related quality of life events and pulmonary toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance

Authors
Category Systematic review
JournalAnnals of Oncology
Year 2018
This article has no abstract
Epistemonikos ID: 6dede794b0454f8c72e43fc2b78c7988456e73b8
First added on: Feb 11, 2025